RVMDW — Revolution Medicines, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1628171 ·
Last close
$1.88
Market Cap
—
52W High
$1.88
52W Low
$1.88
ADV30
0
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -445,222,000 | -453,816,000 | 2,253,737,000 | 440,939,000 | 753,820,000 |
| Dec 2025 | 0 | — | -361,626,000 | -364,892,000 | 2,354,508,000 | 383,745,000 | 723,211,000 |
| Sep 2025 | 0 | — | -315,269,000 | -305,206,000 | 2,251,920,000 | 217,442,000 | 655,016,000 |
| Jun 2025 | 0 | — | -264,714,000 | -247,787,000 | 2,429,568,000 | 402,438,000 | 564,199,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-897,741,000
Investing CF
$118,058,000
Financing CF
$621,524,000
CapEx
$-15,990,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,869,102,000
Inventory
—
Receivables
$0
ST Investments
$1,641,934,000
EBIT TTM
$-1,152,208,000
Pretax Income TTM
$-1,131,301,000
Interest Exp TTM
$23,364,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -1,182,369,000 | -1,131,301,000 | 2,354,508,000 | 723,211,000 | — | -897,741,000 |
| Dec 2024 | 0 | -689,524,000 | -600,093,000 | 2,558,301,000 | 293,097,000 | — | -557,436,000 |
| Dec 2023 | 11,580,000 | -487,185,000 | -436,367,000 | 2,061,705,000 | 235,511,000 | — | -350,572,000 |
| Dec 2022 | 35,380,000 | -258,279,000 | -248,705,000 | 811,930,000 | 126,742,000 | — | -224,401,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $207.87B | $385.16 | — |
| GILD | GILEAD SCIENCES, INC. | $161.66B | $130.21 | — |
| ARGX | ARGENX SE | $53.42B | $853.82 | — |
| RVMD | Revolution Medicines, Inc. | $39.87B | $187.53 | — |
| BIIB | BIOGEN INC. | $29.99B | $202.95 | — |
News headlines (Yahoo Finance, 1h cache)
Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now
2026-07-29 21:20 · Yahoo
Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026
2026-07-29 20:05 · Yahoo
Will FDA Priority Review for Daraxonrasib Redefine Revolution Medicines' (RVMD) Pancreatic Cancer Narrative?
2026-07-25 19:09 · Yahoo
Revolution Medicines (RVMD) Stock Looks Fully Priced With Strong Returns But Weak Value Checks
2026-07-25 18:09 · Yahoo
Revolution Medicines (RVMD) Wins FDA Review Milestone For Daraxonrasib In Pancreatic Cancer
2026-07-25 10:06 · Yahoo
Can Revolution Medicines (RVMD) Justify Its Valuation On Daraxonrasib Survival Data?
2026-07-25 04:21 · Yahoo
Big pharma’s patent cliff meets a new biotech Cold War: We need to outrun China, not outlaw it
2026-07-24 11:30 · Yahoo
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
2026-07-24 09:00 · Yahoo
Summit Therapeutics Q2 Earnings Call Highlights
2026-07-23 22:06 · Yahoo
FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer
2026-07-23 17:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.